Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 321

Sort by

Sort Order Select

Journal Articles

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Martin Müller, MSc, Franz Geisslinger, Susanne Gerndt, Ramona Schütz, Yu-Kai Chao, Franz Bracher, Christian Grimm, Angelika Vollmar, Karin Bartel

Blood (2019) 134 (Supplement_1): 2081.

https://doi.org/10.1182/blood-2019-128195

Published: 2019

Journal Articles

Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute

Youngmin Park, MS, Grace Irene, BS, Amudha Ganapathy, PhD, Dolores Mahmud, PhD, Pritesh Patel, MB, ChB, Damiano Rondelli, MD, Nadim Mahmud, MBBS, PhD

Blood (2019) 134 (Supplement_1): 1968.

https://doi.org/10.1182/blood-2019-132145

Published: 2019

Journal Articles

Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma

Jonahunnatha Nesson George William, PhD, Jian Wu, MD, Ziyan Chen, Omar Faruq, PhD, Hong Chang, MD

Blood (2019) 134 (Supplement_1): 1823.

https://doi.org/10.1182/blood-2019-128917

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Single Cell Sequencing Reveals Heterogeneity of Gene Expression in KMT2A Rearranged Infant ALL at Relapse Compared to Diagnosis

Erin Guest, MD, Byunggil Yoo, MS, Rumen Kostadinov, PhD, Midhat S. Farooqi, MD PhD, Emily Farrow, PhD CGC, Margaret Gibson, Neil Miller, Karina Shah, Tomi Pastinen, MD PhD, Patrick A. Brown, MD

Blood (2019) 134 (Supplement_1): 2756.

https://doi.org/10.1182/blood-2019-131999

Published: 2019

Journal Articles

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Ralph Kamel, Marshall S. Horwitz, MD PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 103.

https://doi.org/10.1182/blood-2019-127409

Published: 2019

Journal Articles

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Vanessa Kohl, MSc, Susanne Brendel, MTA, Johanna Flach, PhD, Helga Kleiner, MTA, Christel Weiss, PhD, Wolfgang Seifarth, PhD, Daniel Nowak, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD, Henning D. Popp

Blood (2019) 134 (Supplement_1): 5056.

https://doi.org/10.1182/blood-2019-122672

Published: 2019

Journal Articles

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Ana M Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, PhD, Andrea Gómez-Llonín, B.Sc., María-Dolores García-Malo, MD, Francisco José Ortuño, Vicente Vicente Garcia, MD PhD, Blanca Espinet, PhD, Andres Jerez

Blood (2019) 134 (Supplement_1): 851.

https://doi.org/10.1182/blood-2019-127960

Published: 2019

Journal Articles

Sickle Cell Hemoglobin Impairs Lysosomal Processing in Macrophages Leading to Inflammasome Activation and Inflammation

Marina Jerebtsova, PhD, Xiaomei Niu, MD, Sharmin Diaz, NP, Namita Kumari, PhD, Sergei Nekhai, PhD

Blood (2019) 134 (Supplement_1): 979.

https://doi.org/10.1182/blood-2019-130741

Published: 2019

Journal Articles

The NSD2 p.E1099K Mutation in Relapse Pediatric Acute Lymphoblastic Leukemia Is Linked to Mercaptopurine Resistance

Jason Saliba, PhD, Joanna Pierro, DO, Nikki Ann Evensen, PhD BS, Anita Qualls, Natasha Belsky, William L. Carroll, MD

Blood (2018) 132 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2018-99-117799

Published: 2018

Journal Articles

An in Vitro Study on the Role of Angiogenesis in Iron Deficiency Induced Reactive Thrombocytosis

Pedro De Alarcon, MD, Manu Gnanamony, PhD, Jessica Garcia, MD

Blood (2018) 132 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2018-99-115378

Published: 2018

Journal Articles

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Giorgia Simonetti, PhD, Samantha Bruno, Carmine Onofrillo, PhD, Cristina Papayannidis, Giovanni Marconi, Michele Cavo, MD, Lorenzo Montanaro, MD PhD, Giovanni Martinelli

Blood (2018) 132 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2018-99-117429

Published: 2018

Journal Articles

Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia

Victoria Y Ling, MBBS, William Godfrey, Sebastien Jacquelin, PhD, Jasmin Straube, PhD, Leanne T Cooper, Claudia Bruedigam, PhD, Siok-Keen Tey, MBBS PhDFRACP FRCPA, Lars Bullinger, MD, Marco J Herold, Megan Bywater, PhD, Steven W. Lane, MD PhD

Blood (2018) 132 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2018-99-115729

Published: 2018

Journal Articles

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

So Hyun Park, BS, Ciaran M Lee, PhD, Yankai Zhang, PhD, Alicia Chang, MD, Vivien A Sheehan, MD PhD, Gang Bao, PhD

Blood (2018) 132 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2018-99-114241

Published: 2018

Journal Articles

Functional Analysis of CD99 Upregulation in Acute Myeloid Leukemia

Vijaya Pooja Vaikari, MS, Jiawen Yang, BS, Mojtaba Akhtari, MD, Houda Alachkar, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5129.

https://doi.org/10.1182/blood-2018-99-120348

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

L-Carnitine Does Not Reduce Cytotoxicity from Induction Chemotherapy for Acute Lymphoblastic Leukemia

Jessica Sea, PhD, Etan Orgel, MD MS, Steven D. Mittelman, MD PhD

Blood (2018) 132 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2018-99-117921

Published: 2018

Journal Articles

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Elise A. Chong, MD, Bruce L Levine, PhD, Stephan A. Grupp, MD PhD, Megan Davis, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Whitney Lynn Gladney, PhD, Noelle V. Frey, MD, David L. Porter, MD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 197.

https://doi.org/10.1182/blood-2018-197

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Taylor Gonzalez, Evan C Catton, Ashley E. Rosko, MD, Yvonne Efebera, MD, Maria Chaudhry, MD, Francesca Cottini, MD, Bethany L Mundy-Bosse, PhD, Tiffany Hughes, BS, PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2018-99-117465

Published: 2018

Journal Articles

Dual Inhibition of Aurora Kinase and BRD4 Leads to Improved Anti-Tumor Activity in Myc-Overexpressing Lymphoma Cells

Steven I Park, MD, Carolina Lin, Lawrence J Druhan, PhD, Michael B Foote, Trevor Parton, Natalie Ren, Steven P Angus, Aadra P Bhatt, Scott C Jaros, Nilanjan Ghosh, MD PhD, Ryan Jacobs, MD, Belinda Rene Avalos, MD, Dirk P Dittmer, PhD, Norman E. Sharpless, MD, Blossom A Damania

Blood (2017) 130 (Supplement 1): 4109.

https://doi.org/10.1182/blood.V130.Suppl_1.4109.4109

Published: 2017

NARROW

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute

Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Single Cell Sequencing Reveals Heterogeneity of Gene Expression in KMT2A Rearranged Infant ALL at Relapse Compared to Diagnosis

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Sickle Cell Hemoglobin Impairs Lysosomal Processing in Macrophages Leading to Inflammasome Activation and Inflammation

The NSD2 p.E1099K Mutation in Relapse Pediatric Acute Lymphoblastic Leukemia Is Linked to Mercaptopurine Resistance

An in Vitro Study on the Role of Angiogenesis in Iron Deficiency Induced Reactive Thrombocytosis

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

Functional Analysis of CD99 Upregulation in Acute Myeloid Leukemia

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

L-Carnitine Does Not Reduce Cytotoxicity from Induction Chemotherapy for Acute Lymphoblastic Leukemia

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Dual Inhibition of Aurora Kinase and BRD4 Leads to Improved Anti-Tumor Activity in Myc-Overexpressing Lymphoma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only